Randomised controlled trial of additional lifestyle support for the reduction of cardiovascular disease through primary care in Stoke-on-Trent, UK

Rachel Davey, Thomas Cochrane, Zafar Iqbal, Giri Rajaratnam, Ruth Chambers, Yvonne Mawby, Linda Picariello, Chris Leesem, Neil Ryder

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The purpose of this trial is to evaluate the effectiveness of providing additional support in modifying lifestyles and in reducing population cardiovascular disease risk compared with usual primary prevention care. A prospective, individually randomised controlled trial design is used, within which groups of patients are clustered by general practice. Multi-level modelling is proposed to account for clustering effects by practice and a two-stage least squares regression approach to account for expected contamination at the analysis stage. The research is set in Stoke-on-Trent, a mid-sized urban city in central England with a generally poor health profile. Patients included will be those aged between 35 and 74 years who have been identified as being at increased risk of developing cardiovascular disease. Approximately 920 patients will be recruited in each arm of the trial (20 control, 20 treatment in each of 46 practices). Usual primary prevention care (control) will be compared with usual primary prevention care plus bespoke lifestyle support (treatment). The primary outcome measure is the Framingham 10-year cardiovascular disease risk at one year. Intermediate outcomes: weight, physical activity and health-related quality of life, will be determined at six months to monitor progress with treatment. Change in individual risk factors: blood pressure, lipid profile, weight, body mass index, waist circumference, smoking, diabetes and cardiovascular disease status and medications will also be measured at one year to help understand the specific mechanisms by which the primary endpoint was achieved.
Original languageEnglish
Pages (from-to)345-354
Number of pages10
JournalContemporary Clinical Trials
Volume31
Issue number4
DOIs
Publication statusPublished - 2010

Fingerprint

Life Style
Primary Health Care
Cardiovascular Diseases
Primary Prevention
Randomized Controlled Trials
Weights and Measures
Urbanization
Waist Circumference
Least-Squares Analysis
General Practice
England
Cluster Analysis
Body Mass Index
Therapeutics
Smoking
Quality of Life
Outcome Assessment (Health Care)
Exercise
Blood Pressure
Lipids

Cite this

Davey, Rachel ; Cochrane, Thomas ; Iqbal, Zafar ; Rajaratnam, Giri ; Chambers, Ruth ; Mawby, Yvonne ; Picariello, Linda ; Leesem, Chris ; Ryder, Neil. / Randomised controlled trial of additional lifestyle support for the reduction of cardiovascular disease through primary care in Stoke-on-Trent, UK. In: Contemporary Clinical Trials. 2010 ; Vol. 31, No. 4. pp. 345-354.
@article{e900bf0a2da5416386483e4207179e88,
title = "Randomised controlled trial of additional lifestyle support for the reduction of cardiovascular disease through primary care in Stoke-on-Trent, UK",
abstract = "The purpose of this trial is to evaluate the effectiveness of providing additional support in modifying lifestyles and in reducing population cardiovascular disease risk compared with usual primary prevention care. A prospective, individually randomised controlled trial design is used, within which groups of patients are clustered by general practice. Multi-level modelling is proposed to account for clustering effects by practice and a two-stage least squares regression approach to account for expected contamination at the analysis stage. The research is set in Stoke-on-Trent, a mid-sized urban city in central England with a generally poor health profile. Patients included will be those aged between 35 and 74 years who have been identified as being at increased risk of developing cardiovascular disease. Approximately 920 patients will be recruited in each arm of the trial (20 control, 20 treatment in each of 46 practices). Usual primary prevention care (control) will be compared with usual primary prevention care plus bespoke lifestyle support (treatment). The primary outcome measure is the Framingham 10-year cardiovascular disease risk at one year. Intermediate outcomes: weight, physical activity and health-related quality of life, will be determined at six months to monitor progress with treatment. Change in individual risk factors: blood pressure, lipid profile, weight, body mass index, waist circumference, smoking, diabetes and cardiovascular disease status and medications will also be measured at one year to help understand the specific mechanisms by which the primary endpoint was achieved.",
author = "Rachel Davey and Thomas Cochrane and Zafar Iqbal and Giri Rajaratnam and Ruth Chambers and Yvonne Mawby and Linda Picariello and Chris Leesem and Neil Ryder",
year = "2010",
doi = "10.1016/j.cct.2010.04.002",
language = "English",
volume = "31",
pages = "345--354",
journal = "Controlled Clinical Trials",
issn = "0197-2456",
publisher = "Elsevier Inc.",
number = "4",

}

Randomised controlled trial of additional lifestyle support for the reduction of cardiovascular disease through primary care in Stoke-on-Trent, UK. / Davey, Rachel; Cochrane, Thomas; Iqbal, Zafar; Rajaratnam, Giri; Chambers, Ruth; Mawby, Yvonne; Picariello, Linda; Leesem, Chris; Ryder, Neil.

In: Contemporary Clinical Trials, Vol. 31, No. 4, 2010, p. 345-354.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Randomised controlled trial of additional lifestyle support for the reduction of cardiovascular disease through primary care in Stoke-on-Trent, UK

AU - Davey, Rachel

AU - Cochrane, Thomas

AU - Iqbal, Zafar

AU - Rajaratnam, Giri

AU - Chambers, Ruth

AU - Mawby, Yvonne

AU - Picariello, Linda

AU - Leesem, Chris

AU - Ryder, Neil

PY - 2010

Y1 - 2010

N2 - The purpose of this trial is to evaluate the effectiveness of providing additional support in modifying lifestyles and in reducing population cardiovascular disease risk compared with usual primary prevention care. A prospective, individually randomised controlled trial design is used, within which groups of patients are clustered by general practice. Multi-level modelling is proposed to account for clustering effects by practice and a two-stage least squares regression approach to account for expected contamination at the analysis stage. The research is set in Stoke-on-Trent, a mid-sized urban city in central England with a generally poor health profile. Patients included will be those aged between 35 and 74 years who have been identified as being at increased risk of developing cardiovascular disease. Approximately 920 patients will be recruited in each arm of the trial (20 control, 20 treatment in each of 46 practices). Usual primary prevention care (control) will be compared with usual primary prevention care plus bespoke lifestyle support (treatment). The primary outcome measure is the Framingham 10-year cardiovascular disease risk at one year. Intermediate outcomes: weight, physical activity and health-related quality of life, will be determined at six months to monitor progress with treatment. Change in individual risk factors: blood pressure, lipid profile, weight, body mass index, waist circumference, smoking, diabetes and cardiovascular disease status and medications will also be measured at one year to help understand the specific mechanisms by which the primary endpoint was achieved.

AB - The purpose of this trial is to evaluate the effectiveness of providing additional support in modifying lifestyles and in reducing population cardiovascular disease risk compared with usual primary prevention care. A prospective, individually randomised controlled trial design is used, within which groups of patients are clustered by general practice. Multi-level modelling is proposed to account for clustering effects by practice and a two-stage least squares regression approach to account for expected contamination at the analysis stage. The research is set in Stoke-on-Trent, a mid-sized urban city in central England with a generally poor health profile. Patients included will be those aged between 35 and 74 years who have been identified as being at increased risk of developing cardiovascular disease. Approximately 920 patients will be recruited in each arm of the trial (20 control, 20 treatment in each of 46 practices). Usual primary prevention care (control) will be compared with usual primary prevention care plus bespoke lifestyle support (treatment). The primary outcome measure is the Framingham 10-year cardiovascular disease risk at one year. Intermediate outcomes: weight, physical activity and health-related quality of life, will be determined at six months to monitor progress with treatment. Change in individual risk factors: blood pressure, lipid profile, weight, body mass index, waist circumference, smoking, diabetes and cardiovascular disease status and medications will also be measured at one year to help understand the specific mechanisms by which the primary endpoint was achieved.

U2 - 10.1016/j.cct.2010.04.002

DO - 10.1016/j.cct.2010.04.002

M3 - Article

VL - 31

SP - 345

EP - 354

JO - Controlled Clinical Trials

JF - Controlled Clinical Trials

SN - 0197-2456

IS - 4

ER -